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Abstract
Background: The effect of antiviral therapy in chronic hepatitis B (CHB) on reducing the risk of long-term
complications (LTCs) remains unclear so far. To study whether long-term nucleos(t)ide analogues therapy can
reduce the risk of long-term complications.
Methods: We searched MEDLINE, EMBASE, OVID, the Cochrane Central Register of Controlled Trials. Relative risks
(RRs) of long-term complications with or without treatment were studied. Also subgroup analyses including the
status of drug-resistance, HBeAg and pre-existing compensated cirrhosis were done using relative risks of long-
term complications either with or without treatment or among nucleos(t)ide analogues treatment groups.
Results: Six eligible studies (3644 patients in all) were included. Data showed the incidence of long-term
complications in treatment groups was induced by 74%(RR:0.26, 95% CI: 0.15-0.47) compared with no treatment.
Whether drug-resistant happened or not during the long-term therapy, the incidence of long-term complications
was still significantly induced respectively by 45%(RR: 0.55,95%CI:0.40-0.76) and 78% (RR:0.22, 95%CI: 0.13-0.36). For
both different status of HBeAg and pre-existing compensated cirrhosis, there was significant lower incidence of
long-term complications in treatment groups compared with no treatment, too. Moreover, among the NA
treatment groups, patients with drug-resistance had 2.64 times (RR:2.64, 95%CI: 1.58-4.41) higher chance of
developing to long-term complications, and patients with pre-existing compensated cirrhosis also had 3.07 times
(RR:3.07, 95%CI: 1.04-9.11) higher chance of developing to long-term complications.
Conclusions: Long-term nucleos(t)ide analogue therapy for adults with CHB prevents or delays the development
of long-term complications including decompensated cirrhosis, CHB-related death or CHB-related HCC in patients
with CHB. The patients who need take antiviral drugs should receive the antiviral therapy as soon as possible.
Background
HBV infection is a common global public health problem
which affects over 400 million people worldwide [1]. It not
only leads to a wide spectrum of liver disease ranging
from acute hepatitis (including fulminant hepatic failure)
to chronic hepatitis [2] but also the main reason of fatal
complications including decompensated cirrhosis and
CHB-related HCC that cause up to one million HBV car-
riers dying of HBV associated liver disease annually [3].
According to natural history, around 15-20% of CHB
patients develop cirrhosis in 5 years of follow-up [4,5].
Those with chronic active hepatitis and cirrhosis on liver
biopsy have a 5-year survival rate of only 55% [6]. The
final goal of treatment for CHB is to induce decompen-
sated cirrhosis, CHB-related HCC or CHB-related death.
Two studies more than 3500 CHB patients in Taiwan
show the risk of developments of HCC and cirrhosis
increases when HBV rapidly replicates, especially after
adjustment for sex, age, alcohol consumption, smoking,
HBeAg status, serum ALT level and liver cirrhosis [7,8]. It
means that suppress of HBV replication may reduce the
risk of long-term complications of CHB infection and
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any medium, provided the original work is properly cited.improve prognosis. Based on this, all guidelines share a
common principle regarding nucleos(t)ide analogues treat-
ment for CHB: long-term viral suppression by the drugs
with potent antiviral activity and low rate of drug resis-
tance to achieve ‘’durable response’’ to prevent hepatic
decompensation, reduce or prevent progression to cirrho-
sis and/or HCC, and prolong survival [9-11].
There are two kinds of oral antiviral agents approved to
treat hepatitis B. Nucleoside analogues include lamivudine,
telbivudine and entecavir, while nucleotide analogues
include adefovir and tenofovir. They all suppress the repli-
cation of HBV in the liver. Studies have shown that treat-
ment of CHB with nucleos(t)ide analog would not only
suppress the viral replication but also reduce fibrosis in the
liver [12-18]. These findings have changed the concept that
fibrosis is irreversible. Consensus has been reached that
treatment must be often administered long-term as the
high rate of virological relapse when nucleos(t)ide analogue
therapy is discontinued. However, long-term therapy may
increase the emergence of resistant viral variants and some-
times may be associated with hepatitis flares, which may
compromise the initial clinical benefit of the treatment. So
far the effect of treatment on reducing the risk of long-term
complications (LTCs) remains unclear. On the other hand,
whether drug-resistant mutation is associated with high risk
of developing long-term complications remains another
open question. The major reasons include relatively small
sample size, lack of adequate controls, short time of follow-
up, different age groups at enrolment and so on.
Traditionally, meta-analysis is applied and best con-
fined to RCTs. However, there were NRCTs [19,20]
chosen into a meta-analysis before when controlled pla-
cebo groups were difficult to perform in the clinical.
According to the available evidence and assessing it by
meta-analysis, we made an effort to compare the effect
of NA therapy vs. no therapy in the incidence of long-
term complications of CHB on the basis of published
data. We also attempted to study the effects of HBeAg
status, pre-existing compensated cirrhosis, virological
response to NA and drug-resistance to NA on the risk
of long-term complications.
Methods
We searched MEDLINE, EMBASE, OVID, the Cochrane
Central Register of Controlled Trials [21] using keywords
“(nucleoside analog OR lamivudine OR entecavir OR
adefovir OR telbivudine OR tenofovir) AND (hepatitis B
OR HBV) AND (cirrhosis OR carcinoma OR cancer OR
hepatic failure OR die OR death)”. The limits were
“human” and “English”. We included all randomized con-
trolled trials, case-control or cohort studies of adults with
CHB published in English between Jan.1998 and Jul.2010,
if they met the following criteria:
(i) Confirmed CHB infection including CHB and
early cirrhosis whose definition was described clearly
in the articles.
(ii) Either NA (lamivudine, adefovir, entecavir, telbu-
vidine, tenofovir) was used for treatment.
(iii) In randomized-control trial (RCT) a control
group with placebo or no antiviral treatment, and in
case-control or cohort study the inclusion of a con-
trol group with no antiviral treatment.
(iv) The final outcome of studies was the number of
incidence of long-term complications such as CHB-
related death, CHB-related HCC or decompensated
cirrhosis diagnosed during the period of study in
both treatment and control groups, and the follow-
ing-up time was more than 2 years.
Patients were excluded if:
(i) Studies with duplicated publications on the same
group of patients, including those reported early
stages of study findings within complete sample size.
(ii) They were children, or pregnant women, or had
several causes of hepatitis such as HCV/HDV/HIV/
autoimmune hepatitis and so on, unless outcomes
for participants meeting our eligibility criteria were
reported separately.
(iii) They had decompensated liver disease or hepa-
tocellular carcinoma at baseline.
(iv) They had received chemotherapy any systemic
antiviral therapy, immunomodulators, cytotoxic
agents, or corticosteroids within 6 months or liver
transplantation before.
(v) Studies with less than 50 cases.
We tried to analysis the various factors which effect
the main outcomes including pre-existing compensated
cirrhosis, drug-resistance to anti-viral agents, HBeAg
status and virological response to treatment on long-
term complications development. Studies lacking clear
definitions of cirrhosis, drug resistance and virological
response were not included in subgroup analysis. Pre-
existing compensated cirrhosis was referred as Ischaks
score of 5-6 and radiological and/or histological diagno-
sis of cirrhosis without evidence of decompensation of
hepatic function and portal hyperion. Drug-resistance
was defined as reappearance of HBV DNA after initial
negativity. Virological response was defined as disap-
pearance of HBeAg with or without appearance of anti-
HBe and undetectable HBV DNA levels.
Denition of long-term complications
Long-term complications of CHB are the end events of
clinic including decompensated cirrhosis which included
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ing, spontaneous bacterial peritonitis or hepatic ence-
phalopathy; HBV-related HCC diagnosed histologically
or by diagnostic imaging method(s), given an alpha feto-
protein (AFP) level above 400 ng/mL; or HBV-related
death.
Quality assessment
Quality of each study was assessed based on following
criteria:
(i) For RCT: random sequence generation, allocation
concealment, blind method, and description of with-
drawals and dropouts. The qualities of the first three
items were classified into three grades respectively:
adequate (2 points), unclear (1 point), and inade-
quate (0 point). And the fourth item was classified
into two grades: described (1 point) and not
described (0 point). The scores of modified Jadad
quality scale were ranged from 0 to 7, with scores ≥
4 signifying high-quality studies.
(ii) For case-control study: case-matched by patient’s
characteristics (age, gender, hepatitis function, per-
centage of pre-existing cirrhosis and HBeAg-positive,
and so on).
(iii) Definitely listing of inclusion and exclusion cri-
teria for patients.
(iv) Clear definitions of treatment response (drug-
resistance and virological response) and long-term
complications diagnosis.
Statistical analysis
Meta-analysis was performed using fixed-effect or
random-effect methods, depending on absence or pre-
sence of significant heterogeneity [22]. Chisquared test
was used to test whether statistical heterogeneity exist-
ing or not and we considered it to have existed when
P < 0.10. Statistical heterogeneity was also assessed with
I
2, which indicates the percentage of total variation
across studies. The random-effect model would be used
if there was significant heterogeneity, otherwise the
fixed-effect model would be used. We used the relative
risk(RR) of the main outcomes as the measure of effi-
cacy. The 95% confidence interval(CI) for the combined
RR is also provided. Analyses were performed with
review manager version4.2.2 (RevMan, The Cochrane
Collaboration, Oxford, England)
Results
Characteristic and quality of studies
1514 abstracts were found, among them eight studies
[23-30], of RCTs and NRCTs eligible in this meta-analy-
sis excluding seven reviews. There were three [23,29,30]
repeated publications at different time points and we
selected only one. The final analysis therefore included six
studies published from 2004 to 2010[23-28] (Figure 1).
The main features of the studies evaluated by meta-
analysis are shown in Table 1. All studies on antiviral
agent used lamivudine[23-28]and two study added (or
switched to) adefovir in case of lamivudine resistance
[24,27].
There were 3644 patients in all, 2035 of whom
received treatment and 1609 didn’t. Among the six
studies[23-28], there were two randomized controlled
trials[23,27], one case-control study[25]and there
cohort studies[24,26,28]. (Table1). One trial was pub-
lished as an abstract[27]and five published as full
publication.
Patients’ selection criteria were different among stu-
dies. One studies[26]included only patients with
HBeAg positive/negative CHB, four studies[23-25,28]
included patients with HBeAg positive/negative CHB
or Child-Pugh A cirrhosis, while one studies[27]
included only patients with HBV-related cirrhosis. The
sample size of each study varied greatly, ranging from
222[27]to 1355[28] patients. The mean age ranged
from 33.7[26]to 52[24]years old for treated patients
and from 33.4[26]to 49[24]years old for untreated
patients. The percentage of males ranged from 72.8%
[25] to 85%[23]. The length of follow up differed
among studies, ranging from 2.7 years[23,25] to
8.2 years[26]. Generally, age, male/female ratio, percen-
tage of pre-existing cirrhosis, and length of follow up
were not signicantly different between treated and
untreated groups in these studies. But the ALT levels
were significantly higher in treated than in untreated
groups in four studies[24-26,28].
Effect of nucleotide/side analogues on development of
LTCs
Data collected from six studies is shown in Table 1.
Generally, LTCs occurred in 4.52%(92/2035) in NA
treatment patients and 13.7%(220/1609) untreatment
patients during following up more than two years. Ran-
dom effect model was used to combine the results since
statistical heterogeneity was found (I
2 =7 6 . 3 % ,P =
0.0008 < 0.10) (Figure 2). The combined RR was 0.26,
(95% CI: 0.15-0.47), and statistical significant (P <
0.00001). These results suggest NA treatment signifi-
cantly decreased the incidence of LTCs compared with
no treatment in a long-term follow-up period.
Subgroup analysis
To investigate the various factors of effecting the develop-
ment of LTCs, we applied subgroup analyses including the
aspects of drug-resistance, HBeAg status or pre-existing
compensated cirrhosis.
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resistance
Comparation between NA treatment and no treatment
Four studies [23,24,26,28] were included. The remaining
two studies[25,27] didn’t report the number of patients
with or without drug-resistance, and we excluded them.
Subgroup analysis with drug-resistance showed a signifi-
cantly lower incidence of LTCs compared NA treatment
(7.0%,65/934) with no treatment (12.0%,134/1120) (RR:
0.55,95%CI:0.40-0.76; Figure 3). Also we found much
fewer events of main outcome between NA treatment
(3.0%, 18/607) and no treatment (12.0%,134/1121) in the
same studies of patients without drug-resistance
[23,24,26,28] (RR:0.22, 95%CI: 0.13-0.36; Figure 4). No
statistical heterogeneity was found in both Subgroups
and fixed effect model was used (Figure 3, P =0 . 4 3>
0.10 and Figure 4, P = 0.49 > 0.10).
Comparation between patients with and without drug-
resistant among the NA treatment groups
We also tried to find out that whether the factors of drug-
resistance could effect the development of LTCs or not
among the treatment groups. There were four studies
[23,24,26,28] reported the number of patients who
occurred LTCs with or without drug-resistance separately.
The patients with drug-resistance had high probability of
LTCs (7.0%, 65/924) than the patients without drug-
resistance (3.0%, 18/607) (Figure 5). No statistical hetero-
geneity was found and fixed effect model was used (P =
0.78 > 0.10, RR:2.64, 95%CI: 1.58-4.41; Figure 5).
Incidence of LTCs according to HBeAg status
Comparation between NA treatment and no treatment
Three studies[23-25] were included. The remaining one
studies[27]was excluded because of lacking the number of
HBeAg-positive patients. It was shown that HBeAg-
negative patients received NA treatment had hugely lower
incidence of LTCs (5.0%,28/563) compared with placebo
(16.6%,71/427) (RR:0.23,95%CI:0.06-0.92; Figure 6).
Among the HBeAg-positive patients there was a numerical
trend of reduced LTCs between the NA treatment (3.4%,
20/587) and no treatment (12.0%,56/468) (RR:0.24, 95%CI:
0.14-0.40; Figure 7). In additio n ,t h e r ew a sn os t a t i s t i c a l
heterogeneity found and fixed effect model was used (Fig-
ure 7, P = 0.43 > 0.10).
We also tried to compare the prognosis of patients
with different HBeAg status among the treatment
groups. Unfortunately, only two studies[23,25] were
available and we didn’t do the meta-analysis.
Incidence of LTCs according to the status of pre-existing
compensated cirrhosis
There were four studies[23,25,27,28] reported the num-
ber of patients with pre-existing compensated cirrhosis,
Figure 1 Results of literature search.* Three studies were published from the same group of investigators [23,29,30]. Only the most updated
publication with a completed dataset was included.
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Study Region Study
type
NA regimens
(/day)
Sample size (n)
(treatment vs.
placebo)
Mean age (ys)
(treatment vs.
placebo)
Male(%)
(treatment
vs. placebo)
Mean ALT(U/L)
(treatment vs.
placebo)
Pre-existing
cirrhosis(%)
(treatment vs.
placebo)
HBeAg (+) (%)
(treatment vs.
placebo)
Mean
treatment
duration
(mon)
Follow
up
period
(ys)
Papatheodoridis
et al.[24]
Greece Cohort LAM 100 or 150
mg then add or
switch to ADV
396 (201 vs. 195) 55.9 (52 ± 11)
vs. (49 ± 14)
82.6 (83.1 vs.
82.1)
83.2 (98 vs. 68) 33.3 (31.8 vs. 34.9) 0 48 3.8
Matsumoto
et al.[25]
Japan Case-
control
LAM 100 mg 754 (377 vs. 377) 41.5 (41.5 ±
12.0) vs. (41.4 ±
12.2)
72.8 (73.2 vs.
72.4)
171.6 (191.7 ±
234.8) vs. (151.5
± 180.5)
17.5 (17.2 vs. 17.8) 54.8 (51.2 vs.
58.4)
18.9 2.7
Yuen et al.[26] Hong
Kong
Cohort LAM 100 mg 266 (142 vs. 124) 33.7 (33.9 vs.
33.4)
73.7 (74.7 vs.
72.6)
61 (65 vs. 56.5) 0 100 (100 vs. 100) 89.9 8.2
Liaw et al.[23] Taiwan RCT LAM 100 mg 651 (436 vs. 215) 43.3 (43 vs. 44) 85 (85 vs. 85) 69.3 (70 vs. 68) 61.3 (60 vs. 65) 58 (58 vs. 58) 32.4 2.7
Eun et al.[27] Korea RCT LAM 100 mg then
add or switch to
ADV
222 (111 vs. 111) M M M 100 M M 4.4
Jong Ryul Eun
et al.[28]
Korea Cohort LAM 1355 (768 vs.
587)
36.8 (39.2 vs.
33.6)
M 152.7 (161.3 vs.
141.4)
50.9 (67.3 vs. 25.2) 85.2 (80.1 vs.
91.8)
More than 48 4.4
M: Data missing in the studies; LAM: Lamivudine; ADV: Adefovir dipivoxil.
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1Figure 3 Forest plots of nucleos(t)ide analogue studies: subgroup analysis on the incidence of LTCs in patients with drug-resistance
between NA treatment and no treatment. Liaw et al * (Figure 3, Figure 4 and Figure 5):two patients had evidence of YMDD mutations at
baseline and five patients no samples after baseline, so data on the emergence of YMDD mutations during therapy were available for 644
patients[23].
Figure 4 Forest plots of nucleos(t)ide analogue studies: subgroup analyses on the incidence of LTCs in patients without drug-
resistance between NA treatment and no treatment.
Figure 2 Forest plot to compare nucleos(t)ide analogues with placebo or no treatment on the incidence of LTCs including
decompensated cirrhosis, CHB-related death or CHB-related HCC.
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Page 6 of 11the remaining one study[24] was excluded because of
lacking the number of patients with pre-existing com-
pensated cirrhosis. We found that NA treatment patient
had less chance of LTCs (8.5%, 63/745) than the
patients without treatment (26.9%, 125/465) (RR:0.28,
95%CI: 0.13-0.58; Figure 8). For patients without pre-
existing compensated cirrhosis, incidence of LTCs in
NA treatment groups is lower (2.0%, 19/947) than no
treatment groups (6.5%, 54/825), too (RR:0.27, 95%CI:
0.16-0.46; Figure 9). No statistical heterogeneity was
found, so fixed effect model was used (Figure 9, P =
0.30 > 0.10).
Comparation between patients with and without pre-
existing compensated cirrhosis among the NA treatment
groups
Prognosis of patients with and without pre-existing
compensated cirrhosis was analyzed among the treat-
ment groups. There were three studies reported the
number of patients who occurred LTCs with pre-
existing compensated cirrhosis, and these patients had
high probability of LTCs (9.1%, 58/634) than the
patients without pre-existing compensated cirrhosis
(2.0%, 19/947) (Figure 10). Statistical heterogeneity was
found and random effect model was used (P =0 . 0 6<
0.10, RR:3.07, 95%CI: 1.04-9.11; Figure 10).
Discussion
The researchers of the REVEAL study analyzed the rela-
tionships between the development of HCC and high
HBV DNA load, according to the natural history of
chronic HBV infection, and the findings of this study
suggested that effective control of HBV replication can
reduce the risk of hepatocellular carcinoma in the long
run theoretically[7]. However, it is still unclear whether
the risk of HCC and other long-term complications can
be decreased by the recommendation of medical treat-
ments including interferon and nucleotide/side analo-
gues. Interferon has been used in the treatment of CHB
for decades. Lots of studies have been reported the
long-term prognosis of interferon, and Y.-F. Yang et al
has generalized a conclusion that IFN prevents or delays
Figure 5 Forest plots of nucleos(t)ide analogue studies: compared the incidence of LTCs between patients with and without drug-
resistant among the NA treatment groups.
Figure 6 Forest plots of nucleos(t)ide analogue studies: subgroup analyses on the incidence of LTCs in HBeAg-negative patients
between NA treatment and no treatment.
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with CHB [31]. Lamivudine was the first nucleoside analo-
gues used as long-term maintenance therapy since the late
1990s, and other nucleotide/side analogues including telbi-
vudine, entecavir, adefovir and tenofovir were approved
recent years. The clinical efficacy and particularly on the
incidence of long-term complications under long-term
antiviral therapy are difficult to monitor because cirrhotic
complications and HCC take long time to develop, espe-
cially in noncirrhotic patients whose incidence of liver-
related complications is even lower. As a result, in most
clinical trials, biochemical response, virologic response
and histologic response [32-34] have been used as surro-
gate end points to determine if the treatment of patients
with chronic HBV infection has been successful. Whether
these surrogate end points can reflect long-term clinical
outcomes was still an open question [35]. Vincent Wai-
Sun Wong at al. has confirmed that normalization of
serum ALT, HBV DNA suppression, HBeAg loss, or
HBeAg seroconversion at the end of drug trials were asso-
ciated but unable to predict long-term clinical outcomes
completely [36]. Even histologic response can’te x a c t l y
reflect the long-term clinical outcomes as regression of
compensated cirrhosis can be translated into favorable
clinical outcome in those treated with long-term nucleo-
tide/side analogues therapy[24].
In this meta-analysis, we choose the clinical end
points including decompensated cirrhosis, CHB-related
death or CHB-related HCC which directly reflect the
prognosis of chronic HBV infection to evaluate the
efficacy of the long-term nucleos(t)ide analogues
therapy.
The most important finding of this meta-analysis is
that more than two years NA therapy for adults with
CHB reduces the risk of LTCs including decompensated
cirrhosis, CHB-related death or CHB-related HCC by
pooling data from six studies[23-28].We also analyzed
the various factors of effecting the risk of LTCs in some
items such as drug-resistance, HBeAg status or pre-
existing compensated cirrhosis, and in any item, NA
therapy was shown the benefit than placebo of reducing
the incidence of LTCs. So for patients with drug-resis-
tance, NA therapy still had a better outcome than the
untreated patients with lower risk of LTCs. Among the
Figure 7 Forest plots of nucleos(t)ide analogue studies: subgroup analyses on the incidence of LTCs in HBeAg-positive patients
between NA treatment and no treatment.
Figure 8 Forest plots of nucleos(t)ide analogue studies: subgroup analyses on the incidence of LTCs in patients with pre-existing
cirrhosis.
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tance effected the risk of LTCs. Then it was found that
the incidence of LTCs were lower in the non-nucleoside
drug resistance groups. At the same time, we compared
the prognosis of patients with and without pre-existing
compensated cirrhosis among the treatment groups.
Then it was found that the incidence of LTCs were lower
in patients without pre-existing compensated cirrhosis. It
suggested us that the earlier antiviral therapy is been
done, the better the prognosis will be. Based on the two
conclusions above, the patients who need take antiviral
drugs should receive the antiviral therapy as soon as pos-
sible. Moreover, and it would be best that drug-resistance
genes were detected before patients administrated the
antiviral drugs, then proper antiviral therapy could be
chosen to reduce the probability of drug-resistance. On
the other hand, management of drug-resistance is abso-
lutely important, too. Patients should regularly be fol-
lowed-up to monitor the drug-resistance. Fortunately,
with the available of newer drugs like adefovir dipivoxil
without cross resistance to lamivudine [37], the problem
of LAM-resistance will go to remission. Currently, add-
on adefovir therapy is the most widely accepted strategy
in case of LAM-resistance. Chen et al.[38] confirmed the
view that the combination of ADV with LAM was super-
ior in inhibiting HBV replication and preventing drug
resistance as compared to ADV alone for LAM-resistant
CHB patients by a meta-analysis. Other nucleotide/side
analogues were available such as entecavir [39-41], teno-
fovir [42] recent years.
There are several limits in our meta-analysis. Firstly
we collected the data from not only randomized con-
trolled trials but also case-control, cohort, and historical
controls studies because of very few RCTs. When
patients are diagnosed CHB or HBV-related cirrhosis
especially with the abnormal liver function and the evi-
dence of HBV replication, it is unethical to running ran-
domized controlled trials. Maybe this is the leading
reason that so few RCTs were conducted. Secondly, the
length of following up differed among studies, ranging
from 2.7 years[23,25]to 8.2 years[26]. As we know, the
longer time of following up, the higher incidence of
LTCs would be seen. So in our meta-analysis, the inci-
dence of LTCs differed significantly. Maybe this is one
Figure 9 Forest plots of nucleos(t)ide analogue studies: subgroup analyses on the incidence of LTCs in patients without pre-existing
cirrhosis.
Figure 10 Forest plots of nucleos(t)ide analogue studies: compared the incidence of LTCs between patients with and without pre-
existing compensated cirrhosis among the NA treatment groups.
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we’ve selected was lacking of testing whether drug-
resistance existed or not before therapy because most of
the studies didn’t show the data about it.
In conclusion, the result of this meta-analysis indi-
cate that long-term nucleos(t)ide analogue therapy for
adults with CHB prevents or delays the development
of long-term complications including decompensated
cirrhosis, CHB-related death or CHB-related HCC in
patients with CHB. The patients who need take anti-
viral drugs should receive the antiviral therapy as soon
as possible. During the monotherapy, when LAM-
resistance happened, lamivudine should be combined
with other antiviral drugs without cross resistance to
lamivudine since it still has more benefit than the
untreated patients.
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